Latest News and Press Releases
Want to stay updated on the latest news?
-
Mechelen, Belgium and Bethesda, Maryland, USA; 29 November 2007 - Galapagos NV (Euronext & LSE: GLPG) and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the non-profit affiliate of the...
-
ETTEPLAN REVISES INTERNATIONAL OPERATIONS Etteplan revises its' international business operations model. The actions to be taken aim to better customer...
-
-------------------------------------------------------------------------------- | Annex of the Rules of the notifications on the transactions in issuer's | | securities concluded by managers...
-
The Q3/2007 interim report of Olympic Entertainment Group AS is available on the Internet homepage of the Tallinn Stock Exchange at http://www.baltic.omxgroup.com/en/market/reports/main...
-
La Food and Drug Administration (FDA) américaine a accepté la demande de mise sur le marché (NDA) de Vimpat(TM) (lacosamide) en tant que thérapie adjuvante des crises d'épilepsie partielle chez les...
-
U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the use of Vimpat(TM) (lacosamide) in the treatment of adults with diabetic neuropathic pain....
-
De Amerikaanse Food and Drug Administration (FDA) heeft de New Drug Application (NDA) voor het gebruik van Vimpat(TM) (lacosamide) voor de behandeling van epilepsie aanvallen met partieel begin bij...
-
De Amerikaanse Food and Drug Administration (FDA) heeft de New Drug Application (NDA) voor het gebruik van Vimpat(TM) (lacosamide) voor de behandeling van diabetische neuropathische pijn aanvaard....
-
U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the use of Vimpat(TM) (lacosamide) as adjunctive therapy in the treatment of partial onset seizures...
-
La Food and Drug Administration (FDA) américaine a accepté la demande de mise sur le marché (NDA) pour l'utilisation de Vimpat(TM) (lacosamide) dans le traitement des douleurs neuropathiques...